By Assoc. Prof. Dr. Mehmet Sorar | Published: 11.02.2025
What Is TMS: Brain-Targeted Stimulation
Transcranial magnetic stimulation (TMS) uses short magnetic pulses from a coil placed on the head to change activity in the brain. It needs no surgery or sedation. It is not one treatment for every condition. In the United States only a short list of uses has regulatory clearance, and Alzheimer's disease and Parkinson's disease are not on it.
What does TMS do to the brain?
According to the Cleveland Clinic's patient page, TMS uses magnetic pulses to change brain activity, and the pulses are given through a coil on the head. No surgery or sedation is needed. That page does not explain in detail how the pulses do this, so phrases such as "waking up" nerve cells or "rewiring" the brain should not be read as established fact.
The field is also wider than a single device. The 2021 guideline from the International Federation of Clinical Neurophysiology (IFCN) updated the 2009 safety advice to cover newer devices and pulse shapes, TMS combined with brain imaging or robot guidance, and TMS combined with electrical stimulation. It applies to healthy volunteers and to patient groups, and it sets minimum training requirements for the people who operate the equipment. The settings that make up a protocol are explained in the page on how TMS protocols are built.
What forms of TMS exist?
TMS comes in several forms, and clearance or evidence for one form does not carry over to another:
- Repetitive TMS (rTMS): repeated magnetic pulses over the course of a session.
- Theta-burst stimulation: a patterned form with much shorter sessions. An intermittent version was first cleared for depression in 2018.
- Deep TMS: a form that reaches broader and deeper brain regions, according to a 2024 systematic review by Di Passa and colleagues.
- Handheld single-pulse devices: used for acute migraine with aura. They are not the same as repetitive TMS.
- Accelerated programmes: several sessions a day over about 5 days, as described by the Cleveland Clinic.
Session lengths and schedules for each form are compared on the page about what a TMS session involves.
Which conditions have regulatory clearance?
In the United States the Food and Drug Administration (FDA) clears TMS devices, or grants them De Novo status (a US route for new types of device), for named conditions. There is no general approval of TMS. The 2022 timeline by Cohen and colleagues and the Cleveland Clinic page give this picture:
| Condition | US regulatory position | Note |
|---|---|---|
| Major depression in adults who have not responded to antidepressants | Cleared. First clearance in 2008, with more devices from 2013. | A European guideline gives Level A (definite efficacy) to high-frequency stimulation of the left prefrontal cortex. |
| Obsessive-compulsive disorder (OCD), as an added treatment in adults | Cleared. First clearance in 2017 according to Cohen and colleagues, 2018 on the manufacturer's page. A second device followed in 2020. | Thin evidence: the Di Passa review found only 2 deep TMS trials controlled with sham (fake) stimulation. |
| Acute treatment of migraine with aura | Cleared for handheld single-pulse devices from 2013, later extended. | A different technology from repetitive TMS. |
| Short-term help with quitting smoking | Cleared for a deep TMS protocol in 2020. | Adults only. |
| Depression with anxiety symptoms (anxious depression) | Listed in the FDA timeline as cleared for one manufacturer's deep TMS device. The manufacturer's page gives 2021. | A deep TMS device. |
| Alzheimer's disease | Not cleared. A De Novo request for a device combining TMS with cognitive training was denied in 2019. | Investigational. Not at Level A or B in the European guideline. |
| Parkinson's disease | Not cleared. The Cleveland Clinic lists it as under study. | Level B (probable efficacy) for motor impairment or depression, using high-frequency stimulation. |
| Bipolar disorder, post-traumatic stress disorder (PTSD), schizophrenia | Not cleared. The Cleveland Clinic lists them as under study. | PTSD reached Level B in the European guideline. |
Clearance and guideline levels measure different things. The 2020 guideline by Lefaucheur and colleagues gave Level A to only three uses: neuropathic pain, depression and hand recovery after stroke. Neuropathic pain and stroke recovery do not appear on the US clearance lists above. Level B applies to a longer list, including Parkinson's disease. The authors also warn that a benefit supported by statistics does not automatically matter in daily life, and the guideline covers literature only to the end of 2018. The detail for each disease is on the pages about TMS in Alzheimer's disease and TMS in Parkinson's disease.
What do "cleared" and "CE-marked" mean?
The FDA clears these devices or grants them De Novo status, so "cleared" is the accurate word, and a clearance covers a named condition and device. A centre that says TMS is "approved" can be asked for which device, which condition and in which country.
The manufacturer BrainsWay says its device holds a European CE mark covering a broader list that includes Alzheimer's disease, Parkinson's disease, bipolar disorder, chronic pain, multiple sclerosis, PTSD and post-stroke rehabilitation. That is the company's own statement, and its page does not say which clinical evidence supports those uses. Because the FDA timeline records the Alzheimer's request as denied in 2019, a CE mark cannot be treated as proof of benefit. These are US decisions. They say nothing about the regulatory position in Türkiye, which a centre can be asked about.
Which exclusions and side effects come with TMS?
The Cleveland Clinic says TMS is not given to people with metal or electronic implants in the head or neck that cannot be removed. Examples are cochlear implants, aneurysm clips or coils, implanted brain stimulators, metal plates and shrapnel. It is also not given to people with pacemakers or defibrillators. Hip or knee replacements and dental fillings are generally considered safe.
The usual side effects are headache, scalp discomfort and mild facial twitching. Seizure is the most serious side effect and is very rare, but the risk is higher in people with epilepsy or a seizure history. A seizure or loss of consciousness away from the clinic needs emergency help, and the treating team should be told afterward. Figures from different sources, and what to do about symptoms, are on the page about TMS safety data.
Sources
- Cleveland Clinic: Transcranial Magnetic Stimulation (TMS)
- Cohen et al.: A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices, Brain Stimulation 2022
- Lefaucheur et al.: Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018), Clinical Neurophysiology 2020
- Rossi et al.: Safety and recommendations for TMS use in healthy subjects and patient populations (IFCN expert guidelines), Clinical Neurophysiology 2021
- Di Passa et al.: Clinical efficacy of deep transcranial magnetic stimulation (dTMS) in psychiatric and cognitive disorders: A systematic review, Journal of Psychiatric Research 2024
- BrainsWay (device manufacturer, commercial source): What Mental Health Conditions Is Deep TMS FDA-Cleared To Treat?
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: TMS Tedavisi